| P2093 | author name string | Melvin E Klegerman | |
| P2860 | cites work | Endoscopic management of hypertensive intraventricular haemorrhage with obstructive hydrocephalus | Q21261386 |
| | Dynamic changes of inflammatory markers in brain after hemorrhagic stroke in humans: a postmortem study | Q24634239 |
| | An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 |
| | Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences | Q28647076 |
| | Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin | Q28647081 |
| | Neutrophil recruitment and function in health and inflammation | Q29616689 |
| | Tissue plasminogen activator for acute ischemic stroke | Q29619377 |
| | Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. | Q30448853 |
| | Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model--brief report. | Q30470200 |
| | Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes | Q30477053 |
| | Ultrasound-enhanced thrombolysis using Definity as a cavitation nucleation agent. | Q30479478 |
| | Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes | Q30480851 |
| | Tissue plasminogen activator concentration dependence of 120 kHz ultrasound-enhanced thrombolysis. | Q30485761 |
| | A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke | Q30488406 |
| | Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. | Q30502198 |
| | Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. | Q31131780 |
| | Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data | Q33194724 |
| | Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke | Q33218220 |
| | Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets | Q33314508 |
| | Advances in the medical management of acute coronary syndromes | Q33655204 |
| | The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy | Q33669873 |
| | The ideal fibrinolytic: can drug design improve clinical results? | Q33736560 |
| | Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin | Q33881226 |
| | Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization | Q33895700 |
| | The plasminogen activator system: biology and regulation | Q34158966 |
| | Ultrasound-enhanced thrombolysis | Q34232098 |
| | Fibrin-mediated plasminogen activation | Q34311780 |
| | Fibrinogen alpha C domains contain cryptic plasminogen and tPA binding sites. | Q34311825 |
| | Bolus fibrinolytic therapy in acute myocardial infarction | Q34315281 |
| | The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies | Q34319954 |
| | Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure | Q34322056 |
| | Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo | Q34360168 |
| | Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. | Q34425337 |
| | Thrombolysis for acute myocardial infarction | Q34468582 |
| | Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis | Q34523260 |
| | A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function | Q34529714 |
| | Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery | Q35049195 |
| | The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. | Q35144575 |
| | Thrombolysis: newer thrombolytic agents and their role in clinical medicine | Q35574270 |
| | Streptokinase--a clinically useful thrombolytic agent. | Q35617262 |
| | A systematic review of barriers to delivery of thrombolysis for acute stroke | Q35666194 |
| | Tissue-type plasminogen activator: a historical perspective and personal account | Q35752943 |
| | Lipid contribution to the affinity of antigen association with specific antibodies conjugated to liposomes | Q36087293 |
| | In vivo behaviour of vesicular urokinase | Q36105037 |
| | The fibrinolytic activity of urine. | Q36131451 |
| | Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion | Q36238215 |
| | Streptokinase: cloning, expression, and excretion by Escherichia coli | Q36270588 |
| | Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. | Q36295006 |
| | Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis. | Q36297030 |
| | Urokinase-type plasminogen activator | Q36659755 |
| | Technology Insight: recanalization with drugs and devices during acute ischemic stroke | Q36700051 |
| | Vitamin A: a drug for prevention of restenosis/reocclusion after percutaneous coronary intervention? | Q37019117 |
| | Review of tissue plasminogen activator, ischemic stroke, and potential legal issues | Q37322970 |
| | Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions | Q37364671 |
| | The role of urokinase-type plasminogen activator in aggressive tumor cell behavior | Q37835073 |
| | How to make better use of thrombolytic therapy in acute ischemic stroke | Q37889116 |
| | Functionalized carriers for the improved delivery of plasminogen activators | Q37973569 |
| | The dynamics of the coronary collateral circulation | Q38176236 |
| | Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction | Q39220756 |
| | Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life | Q39561202 |
| | An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy | Q39669477 |
| | Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells. | Q40142332 |
| | Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels | Q40288670 |
| | Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition | Q40371964 |
| | How safe is the readministration of streptokinase? | Q40423102 |
| | Intimal hyperplasia, vascular modeling, and the restenosis problem | Q40763675 |
| | A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic | Q40780195 |
| | Molecular biology of plasminogen activators: what are the clinical implications of drug design? | Q41303102 |
| | Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro | Q41865204 |
| | Localization in the fibrinogen gamma-chain of a new site that is involved in the acceleration of the tissue-type plasminogen activator-catalysed activation of plasminogen | Q41894885 |
| | Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile | Q42028534 |
| | Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase | Q42071825 |
| | A new biocompatible nanoparticle delivery system for the release of fibrinolytic drugs | Q42816181 |
| | Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research | Q43162275 |
| | Antibodies to streptokinase | Q43186648 |
| | The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. | Q43298207 |
| | Serpin-resistant mutants of human tissue-type plasminogen activator | Q43513355 |
| | Purification and characterization of a melanoma cell plasminogen activator | Q44032827 |
| | Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy | Q44522894 |
| | The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. | Q44640417 |
| | Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin | Q44976756 |
| | The sequence gamma-(312-324) is a fibrin-specific epitope | Q45206324 |
| | Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes | Q45870128 |
| | Experimental study of the preparation of targeted microbubble contrast agents carrying urokinase and RGDS. | Q45950477 |
| | The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study | Q46217933 |
| | Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis | Q46783548 |
| | Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators | Q46807104 |
| | Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. | Q46864819 |
| | A covalent molecular weight approximately 92,000 hybrid plasminogen activator derived from human plasmin fibrin-binding and tissue plasminogen activator catalytic domains | Q47193629 |
| | Covalent molecular weight approximately 92 000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domains | Q47207689 |
| | Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study | Q47247627 |
| | Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke | Q47709702 |
| | Fibrinolytic activity of normal urine | Q47814506 |
| | Utilization of intravenous tissue plasminogen activator for acute ischemic stroke | Q47945527 |
| | Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study | Q47961940 |
| | Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase--a bacterial plasminogen activator | Q48334316 |
| | Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli | Q48400430 |
| | Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage | Q48416205 |
| | Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility | Q48903469 |
| | Water-soluble urokinase derivatives with increased affinity to the fibrin clot | Q49165169 |
| | Improvement of in vitro thrombolysis employing magnetically-guided microspheres. | Q50673356 |
| | The adhesive strength of non-spherical particles mediated by specific interactions. | Q51174053 |
| | RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. | Q51558957 |
| | Distributed intraclot thrombolysis: mechanism of accelerated thrombolysis with encapsulated plasminogen activators. | Q51626516 |
| | Thrombus localization by using streptokinase containing vesicular systems. | Q51800540 |
| | Studies on the kinetics of plasminogen activation by tissue plasminogen activator | Q52434344 |
| | In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model. | Q53589220 |
| | Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. | Q53653055 |
| | ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs. | Q53675674 |
| | The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. | Q53824140 |
| | Characteristics of glycosylated streptokinase secreted from Pichia pastoris: enhanced resistance of SK to proteolysis by glycosylation. | Q54052219 |
| | Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. | Q54576127 |
| | Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots | Q56989863 |
| | Stability of protein-encapsulating DRV liposomes after freeze-drying: A study with BSA and t-PA | Q57103488 |
| | Targeted Thrombolysis by Using of Magnetic Mesoporous Silica Nanoparticles | Q57380545 |
| | Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke | Q57757056 |
| | Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS) | Q57914012 |
| | Time course and importance of neoadventitial formation in arterial remodeling following balloon angioplasty of porcine coronary arteries | Q58657471 |
| | Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy | Q59096199 |
| | Synthesis, Characterization, andin VitroActivity of Dendrimer−Streptokinase Conjugates | Q61855794 |
| | Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator | Q67277823 |
| | Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator | Q67293134 |
| | Interactions between the Finger and Kringle-2 Domains of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-11 | Q67487822 |
| | Development of a procedure for coupling the homing device glu-plasminogen to liposomes | Q67544770 |
| | Plasminogen activator from human embryonic kidney cell cultures. Evidence for a proactivator | Q67547675 |
| | Reduction of thrombus formation in vivo using a thrombolytic agent targeted at damaged endothelial cells | Q67573144 |
| | Fibrinogen-immobilized urokinase demonstrates increased thrombolytic activity in animal experiments | Q67684346 |
| | Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo | Q67901701 |
| | Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation | Q67925871 |
| | The sequence A alpha-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen | Q68031221 |
| | Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential | Q68172189 |
| | Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model | Q68362206 |
| | The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin | Q68368784 |
| | Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase | Q68715387 |
| | Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin | Q69139588 |
| | Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate | Q69149480 |
| | Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group | Q69914426 |
| | Hepatic clearance of tissue-type plasminogen activator in rats | Q69980157 |
| | On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells | Q69980198 |
| | Adaptation of plasminogen activator sequences to known protease structures | Q70262606 |
| | A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators | Q70287614 |
| | Some properties of tissue-type plasminogen activator reconstituted onto phospholipid and/or glycolipid vesicles | Q70347955 |
| | Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction | Q70401895 |
| | Tissue plasminogen activator: chemical and physiological aspects | Q70468659 |
| | Functional properties of carbohydrate-depleted tissue plasminogen activator | Q70515458 |
| | On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture | Q70538450 |
| | Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer | Q70565913 |
| | Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator | Q70789598 |
| | Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells | Q70798607 |
| | The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage | Q71567046 |
| | Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons | Q71571257 |
| | Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature | Q71804313 |
| | Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators | Q71823699 |
| | Isolation of two variants of native one-chain tissue plasminogen activator | Q71841895 |
| | Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA | Q72041876 |
| | Superficial Accumulation of Plasminogen During Plasma Clot Lysis | Q72050300 |
| | Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen | Q72252500 |
| | Experimentally targeted thrombolytic therapy. Application of modified thrombin conjugated with urokinase | Q72324888 |
| | Immobilized Thrombolytic Enzymes Possessing Increased Affinity toward Substrate | Q72380925 |
| | The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction | Q72585330 |
| | Preparation of polyethylene glycol-modified streptokinase with disappearance of binding ability towards anti-serum and retention of activity | Q72675990 |
| | Regulation of virulence factor expression in group A streptococcus | Q73134110 |
| | Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites | Q73313392 |
| | Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model | Q73553873 |
| | Reduction of background activity through radiolabeling of antifibrin Fab' with 99mTc-dextran | Q74068143 |
| | Preparation of a novel streptokinase mutant with improved stability | Q74604947 |
| | In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions | Q77448524 |
| | Prolonged systemic delivery of streptokinase using liposome | Q77753923 |
| | ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface | Q78806398 |
| | Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction | Q79917799 |
| | Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin | Q80043945 |
| | Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide | Q80234435 |
| | Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis | Q80836287 |
| | Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator | Q81497174 |
| | Thrombolytic agents | Q81668310 |
| | Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels | Q84531861 |
| | Streptokinase loading in liposomes for vascular targeted nanomedicine applications: encapsulation efficiency and effects of processing | Q84595360 |
| | The preparation of a new self-made microbubble-loading urokinase and its thrombolysis combined with low-frequency ultrasound in vitro | Q84957602 |
| | Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis | Q84963559 |
| | Effect of subconjunctivally injected liposome-encapsulated tissue plasminogen activator on the absorption rate of subconjunctival hemorrhages in rabbits | Q85007642 |
| | Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents | Q85246497 |
| | A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound | Q85467925 |
| | Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis | Q87086262 |
| | Catabolism of human tissue plasminogen activator in mice | Q93606123 |
| | Fibrin targeting of tissue plasminogen activator-loaded echogenic liposomes | Q94518570 |
| P433 | issue | 1 | |
| P921 | main subject | thrombolysis | Q1931577 |
| P304 | page(s) | 1-19 | |
| P577 | publication date | 2017-01-23 | |
| P1433 | published in | Frontiers of medicine | Q26867043 |
| P1476 | title | Translational initiatives in thrombolytic therapy | |
| P478 | volume | 11 | |